Luminex LMNX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Luminex LMNX

LMNX 36.55

-3.2%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who started this subject	8/15/2002 1:33:58 AM
From: mopgcw	of 11

Luminex Corp Announces Letter Of Intent DOW JONES NEWSWIRES AUSTIN, Texas -- Luminex Corp. (LMNX) signed a nonbinding letter of intent to sell its Rules-Based Medicine research and development project to a new company headed by Mark B. Chandler, Luminex's current chairman, chief executive and president. In a press release Wednesday, Luminex said Chandler will resign to take on the new role but will continue as a director of Luminex and will have a one-year consulting contract. A definitive agreement is expected later this month. Luminex is expected to receive a preferred stock and common stock interest in the newly formed company. Luminex will also license certain technology and supply microspheres to it. G. Walter Loewenbaum, chairman of the executive committee, will succeed Chandler as chairman of the board. Luminex also said that Thomas W. Erickson joined the company as interim president and CEO for an initial six-month engagement. Company Web site: luminexcorp.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next